Enzastaurin and Bevacizumab in Treating Patients With Locally Advanced or Metastatic Cancer

DISEASE CHARACTERISTICS:

* Histologic or cytologic diagnosis of locally advanced or metastatic cancer for which no preferable therapy exists
* Measurable or nonmeasurable disease
* No CNS metastases or a primary CNS tumor

PATIENT CHARACTERISTICS:

* ECOG performance status 0-2
* Life expectancy ≥ 12 weeks
* WBC count ≥ 3.0 × 10\^9/L
* Absolute neutrophil count ≥ 1.5 × 10\^9/L
* Platelet count ≥ 100 × 10\^9/L
* Hemoglobin ≥ 10 g/dL (6.21 mmol/L)
* Bilirubin ≤ 2 times upper limit of normal (ULN)
* Alkaline phosphatase ≤ 3 times ULN (5 times ULN if liver metastases are present)
* AST and ALT ≤ 3 times ULN (5 times ULN if liver metastases are present)
* Serum creatinine \< 1.5 times ULN
* No proteinuria at baseline, as demonstrated by either of the following:

  * Urine protein:creatinine ratio \< 1.0 at screening
  * Urine dipstick for proteinuria \< 2+ (patients discovered to have ≥ 2+ proteinuria on dipstick urinalysis at baseline must undergo a 24-hour urine collection that demonstrates ≤ 1 g of protein in 24 hours to be eligible for study participation)
* No second primary malignancy that could affect compliance with the study or interpretation of the study results
* No concurrent serious systemic disorder (e.g., active infection, including HIV) that, in the opinion of the investigator, would compromise the patient's ability to adhere to the study
* No known hypersensitivity to bevacizumab or enzastaurin hydrochloride, or to a component of either drug
* No prior bevacizumab-related toxicity requiring discontinuation, such as a thromboembolic event, hemorrhage, or serious hypertension
* No clinically significant cardiac disease, in the opinion of the investigator, including any of the following:

  * Myocardial infarction within the past 6 months
  * Symptomatic angina pectoris
  * Congestive heart failure not controlled by medications
  * ECG abnormalities indicative of clinically significant cardiac disease
* No evidence of bleeding diathesis or coagulopathy
* No nonhealing cutaneous wound or gastrointestinal ulcer
* No history of or risk for abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within the past 6 months
* No hemoptysis requiring medical attention within the past 3 months
* No known history of cerebrovascular accidents or transient ischemic attacks
* No clinically significant vascular or peripheral vascular disease
* No hypertension not controlled by medical management
* No history of hypertensive crisis or hypertensive encephalopathy
* No significant traumatic injury within the past 28 days
* Able to comply with study or study procedures
* Able to swallow tablets
* Exhibits compliance and geographic proximity that allow adequate follow-up
* Not pregnant or nursing
* Negative pregnancy test
* Fertile patients must use effective contraception during and for 3 months after completion of study treatment

PRIOR CONCURRENT THERAPY:

* Recovered from prior therapy
* No prior participation in this study or any other study involving enzastaurin hydrochloride
* At least 4 weeks since prior chemotherapy (6 weeks for mitomycin C or nitrosoureas)
* At least 4 weeks since prior radiotherapy, anticancer hormone therapy, or other investigational therapy

  * Patients with hormone-refractory prostate cancer receiving luteinizing hormone-releasing hormone analogue therapy (leuprolide or goserelin) prior to study enrollment should continue therapy during study participation
* At least 6 weeks since prior bicalutamide
* At least 4 weeks since prior flutamide or nilutamide
* More than 10 days since prior and no concurrent aspirin \> 325 mg/day
* More than 28 days since prior major surgery or open biopsy
* More than 7 days since prior core biopsy or other minor surgical procedure, excluding placement of a vascular access device
* No concurrent carbamazepine, phenobarbital, or phenytoin
* No concurrent systemic anticoagulation
* No concurrent chronic use of other nonsteroidal anti-inflammatory drugs
* No concurrent routine use of colony-stimulating factors
* No concurrent major surgery
* No other concurrent chemotherapy, radiotherapy, immunotherapy, or experimental medications
* No other concurrent antitumor therapy